At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 129 enrolled
Drug / intervention
AHB-137 injection +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Single Ascending Doses and Multiple Doses of AHB-137 in Healthy Participants and HBeAg-negative CHB Patients Receiving Stable Nucleos(t)Ide Analogues (NAs) Treatment
In Brief
A Phase 2 clinical trial evaluating AHB-137 injection and Placebo for Hepatitis B, Chronic. Completed, enrolled 129 participants across 3 sites.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy participants after single and multiple doses, and evaluate the preliminary efficacy of AHB-137 in CHB participants after up to 24 weeks of treatment as a proof-of-concept.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis B, Chronic
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartAug 2023
First PostedNov 2023
Primary CompletionDec 2024
Study CompletionNov 2025
TodayJul 2026
First PostedNov 3, 2023
Enrollment StartAug 3, 2023
Primary CompletionDec 3, 2024
Study CompletionNov 10, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.7 years ago
Interventions
AHB-137 injectiondrug
AHB-137 injection will be administered subcutaneously.
Placebodrug
Placebo will be administered subcutaneously.